Arexvy was ~82% effective in preventing RSV-induced lower respiratory tract infections in adults aged 60 or more years.
FDA approval of new COVID-19 boosters could come by Friday
Sep 07, 2023
The new booster targets the XBB.1.5 omicron subvariant, which is similar to the dominant variant now circulating.
FDA approves Voquezna for erosive esophagitis, GERD
Nov 07, 2023
A Phase 3 trial showed noninferiority versus lansoprazole in healing and maintenance phases.
New drug for Alzheimer’s disease shows promise in phase 3 trial
Sep 28, 2022
Lecanemab is a monoclonal antibody drug designed to target and help remove Alzheimer’s-associated amyloid plaques in the brain.
NIH investigating COVID-19 experiments conducted at Boston University
Oct 19, 2022
The US National Institutes of Health is investigating COVID-19 experiments at Boston University that have sparked a media firestorm, with some news outlets alleging that scientists created a “killer”...
CDC panel gives support to new COVID-19 booster shots
Sep 13, 2023
The new booster targets the XBB.1.5 omicron subvariant, which is similar to the dominant variant now circulating.
FDA approves first pill for fecal transplant therapy
Apr 27, 2023
Vowst is approved to prevent recurrence of C. difficile/ The pill contains live gut bacteria from stool samples donated by healthy people.
Biden nominates head of National Cancer Institute to run NIH
May 15, 2023
The new director will face potential scrutiny from both Republicans and Democrats.
Staffing shortages at nursing homes continue: report
Mar 01, 2024
Although the pandemic has ended, staffing shortages and employee burnout still plague US nursing homes, a new government report finds.
Less than one-quarter of patients hospitalized for CVD receive dietary counseling
Jun 18, 2024
The findings were seen across hospitalizations for acute myocardial infarction, congestive heart failure and percutaneous coronary intervention.